Boehringer Ingelheim Commits to Veeva Vault CRM
Top biopharma company selects the next generation of CRM for life sciences as…
International Cancer Organizations Present Collaborative Work During Oncology Event in China
The National Comprehensive Cancer Network (NCCN) is honored to participate in the…
James Dyson Award announces its 2024 global winners: Hair-loss prevention device for chemotherapy patients and Sustainable ‘maple seed’ weather balloon
NEW DELHI, Nov. 14, 2024 /PRNewswire/ -- The James Dyson Award unveils its…
NABH INTEGRATES FOGSI’S MATERNAL HEALTH STANDARDS ACROSS ITS CERTIFICATION PROGRAMS
The MoU signed in 2022 has progressed and culminated in the subsumption of…
This Diabetes Day Heal Beyond Medicine with Dharana at Shillim
MUMBAI, India, Nov. 14, 2024 /PRNewswire/ -- In today's fast-paced world, diabetes…
Foundation for Sarcoidosis Research (FSR) receives confirmation from the Department of Labor (DOL) ensuring patient access to FMLA for participation in clinical trials
CHICAGO, Nov. 16, 2024 (GLOBE NEWSWIRE) -- In August of 2023, the…
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban
November 16, 2024 16:38 ET | Source: Anthos Therapeutics Data presented at…
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence…
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated…
Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024
Two New Analyses from SEQUOIA-HCM Demonstrate Treatment with Aficamten Improves Post-Exercise Oxygen…
